VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Apoptosis
Cell Line, Tumor
Cell Movement
Disease Models, Animal
Drug Resistance, Neoplasm
Extracellular Signal-Regulated MAP Kinases
Gene Expression
Humans
Indoles
Melanoma
Phosphorylation
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins c-akt
Receptor, EphA2
Sulfonamides
Tumor Burden
Up-Regulation
Xenograft Model Antitumor Assays
authors with profiles
JENNIFER WARGO